Following its broad structural analysis of the human SLC transport protein family, MitoCareX advances from a pool of candidates to a prioritized target, reflecting continued execution of its MITOLINE®-driven discovery

NXTS

Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign

Nexentis advances MITOLINE pipeline with prioritized SLC target

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Following its broad structural analysis of the human SLC transport protein family, MitoCareX advances from a pool of candidates to a prioritized target, reflecting continued execution of its MITOLINE®-driven discovery</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Nexentis says its MitoCareX narrowed a broad SLC transport pool to a single, high-potential drug-discovery target using MITOLINE. The move advances its pipeline strategy and could yield near-term milestones or partnerships if the candidate progresses, while the company also highlights a solar RTB investment footing that could influence cash flow.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>MitoCareX narrows SLC candidates to a priority drug-discovery target.</li><li>MITOLINE enables the focused pipeline decision at Nexentis.</li><li>MitoCareX identified a candidate for a drug-discovery campaign.</li><li>Nexentis expands exposure to European renewable assets via RTB.</li><li>Forward-looking statements emphasize capital needs and regulatory risks.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Nexentis Technologies Inc. (NXTS)</strong>: Announces prioritization of a legacy SLC target; potential near-term pipeline catalyst.</li><li><strong>MitoCareX Bio Ltd.</strong>: Selected priority target for MITOLINE-based drug discovery; strategic pivot in SLC program.</li><li><strong>Solterra Renewable Energy Ltd.</strong>: Introduced four solar projects; supports Nexentis&#039; RTB renewable strategy.</li><li><strong>Solterra Energy Ltd.</strong>: Parent company associated with RTB solar platform; potential indirect cash-flow implications.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments with biotech R&amp;D progress; fits Nexentis’ strategy of translating computational insights into concrete discovery decisions and diversifying cash-flow via RTB renewable assets.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>MITOLINE-driven target prioritization could trigger milestone announcements.</li><li>Nexentis&#039; RTB solar investments may influence balance sheet and sentiment.</li><li>Forward-looking disclosures introduce execution and capital-risk considerations.</li><li>No formal financial guidance disclosed; potential dilution risk if funded.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date of release: July 28, 2026.</li><li>MitoCareX narrowed pool to a priority candidate for drug discovery.</li><li>MitoCareX Bio Ltd. is a wholly owned Nexentis subsidiary.</li><li>NXTS trades on NASDAQ under ticker NXTS.</li><li>Nexentis is lead investor in four solar projects across three EU countries via RTB.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>NXTS may drift higher on pipeline progress; catalysts expected within 6–12 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p><i>Following its broad structural analysis of the human SLC transport protein family, MitoCareX advances from a pool of candidates to a prioritized target, reflecting continued execution of its MITOLINE</i><sup><i>&#xAE;</i></sup><i>-driven discovery strategy</i></p>  <p align="justify">Ness Ziona, Israel, July  28, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=1txKJgEl1_qdJ1R34sDUaH9TNXJRIi-glO6Wu9hezANjR8KM0i4jBwiHfXBIPGK8VAOyqgIPsHRZDIgr-uSHZCg8AirfSjKQX28xgd8Xahk=" rel="nofollow" target="_blank">Nexentis Technologies Inc.</a> ("Nexentis"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/NXTS">NXTS</a>) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (&#34;MitoCareX&#34;), has narrowed its focus from the broader pool of SLC transport protein candidates previously identified through its structural analysis efforts, selecting a candidate for a drug discovery campaign.</p>  <p align="justify">As previously disclosed, MitoCareX&#39;s broad structural analysis identified a set of SLC transport proteins outside its mitochondrial program that appeared compatible with the MITOLINE<sup>&#xAE;</sup> enabled structural modelling. Building on that work, the Company has now completed an internal prioritization process and identified a candidate supported by favorable characteristics for inclusion in a drug discovery campaign.</p>  <p align="justify">&#34;This step reflects continued execution of our drug discovery strategy and tangible progress in translating the breadth of our platform into a focused, actionable pipeline decision,&#34; said David Palach, Chief Executive Officer of Nexentis Technologies Inc. &#34;Having previously mapped a broader universe of transport protein candidates, we have now taken the next step of narrowing that pool to a priority candidate. We view this as an important example of how MITOLINE<sup>&#xAE;</sup> can systematically convert computational insight into concrete discovery decisions over time.&#34;</p>  <p align="justify"><b>About MitoCareX Bio Ltd.</b><br></br>MitoCareX Bio Ltd. is a drug discovery company. By combining its proprietary MITOLINE<sup>&#xAE;</sup> algorithm and diverse computational tools with specialized biological systems, MitoCareX aims to generate programs in areas of high unmet medical need.</p>  <p align="justify"><b>About</b> <b>Nexentis</b> <b>Technologies</b> <b>Inc.</b><br></br>Nexentis Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/NXTS">NXTS</a>) owns 100% of <a href="https://www.globenewswire.com/Tracker?data=kt34_zEeb4IarlITSKYmjhdovJ9bGn5a9sVQRIQmxjlcqm677vLFb3vAnhYozdIaunZ-9vPRCUsO-reupCdDbXXVmjsbOJwdekHA_M5EM1bszOMgt5BRZX8fXQFHBfQd7TzpyyiiUYDyidxwwUKPtprC70uBAmXU916OQxv05p7TRip9oOix2BL3_TRSgJ5LnsO6obXdjuSEm71lLXWGcEiPTfQv0bDX1y-StHkyJjIFcG45So9pX-V5r_ANcFqRFmXH_6Fvua-B7AKABYYUIkmBgFj4DbixixtFl8IcjFtp2QHkD4kaK2f6yFgOZv0rfzfC4Ci92HCylZJ-wAUgrnuney1mWp4TuvrvVZFFiwzmECG9dTm5KgsMfGnmKlYX9zwHn4xLoUNoUXSxdT3ka0yXJ4YbETehY6fk1zRqx5I=" rel="nofollow" target="_blank">MitoCareX</a> <a href="https://www.globenewswire.com/Tracker?data=reZqY2i4E2CGDfbE05SwXqbNSGLFmTrq8MJ1ZNQZeqC_hFZCLAD7mer_BwRXwKGvYILUshL_ecdLDHf3t1RD3BOLiEtN48mZpv2SexmQQA0ChhAKprGQ4lP8AIwLVeSHoJtLcFN4Cxll9BCzsdgkIObKyY3tcUi6JXA-Qvi8BAoOHVbOeX4hG3xzzBQ-D6V9f9xImo3Z3dZ-m65DC3vBRqtx9PXXBSHBKA5ZGuZc2igBzKZVt-tywD7xWKyLUcqIhoGEhBRPtWHAFAi-xGVjaVYQbdCVjddC_FjALy_5V_AyxuqjnaWtLapOosKeCkUU1DKaYDez92E0_g89lFlHnMtqSkMmlpQkTyAVdF9Q4-DHC63fNv0K76ckAMHOLopFFF655HSSUEjand23Ww2EAN-ZKOgfpH-z040iSY6dKg0=" rel="nofollow" target="_blank">Bio</a> <a href="https://www.globenewswire.com/Tracker?data=jWOXsMLBPEwIzwLepOdmKZ4tXLV_a1HbxSkOS3P74qJF7f-CT1C036QtZRtejD9cnBWlG0BOdfLxozQAVQhlWAKolxoldOKuuMW8bBd3B3PFv8lVRqWpfhqYOX8kjUNGof8XIoJVHznaggR6Mbb6IaXXR64r6obZZ9TFXz-fS4F8g1610Ym3c6k3Jyyw7e7l90XNOkAORjPSfw6Vk-NOIAtT7dLqSFCP3MZNQnBwNx5SonIjWC8kw4YNn6U49ZwejzNy5Piqirh4xkcDA9dFRI-o7VHmay9xeivPX41I9c805NcM74ojy5SR-SWU6ze8_TDKLi0sFZJRQTlhAWwI4Kc04HHRKVRrGbenb2CnkHjlrzGrLVIzJvgpqGMJO-rFrkODp5X9E0xUnmlen2pHGzdc_xBagtg4fOf9frRlHyQ=" rel="nofollow" target="_blank">Ltd</a>, a drug discovery company. Additionally, Nexentis adopted an investment strategy focused on European renewable energy assets utilizing a <a href="https://www.globenewswire.com/Tracker?data=MW8_axuJyWtPlo0rbLarbJGS0gGmtBnj6c0ebzeaIJE3ERYwKIvVKEcpnoXpPETC4lPFfryx6v5J0js-kqaVk-ek-rHndyTpPQtrZ7QVuxf_Nyw053f_WkACi1_df471txYp6DTs6FeEqcT1f0x8Ua1Li3S0oBZ3daQ7iRNYXDlsrl1SEEKeEKXoEOUfKfC8w9cHMizikbT-pM6gcZ0BTExtpYEDyueJwpTfbdy_9Ea-NUbb6OgajkRqPrjg30BorGqI3Hf6kq60OP-LOPgI5DBLKPxPJmGfhGfzIaF9d0NYEIw1_UW8Ef6COnlAUWYbM-OSicXTkU5_pexMKM5OUV1ara-dyAEKqQGdCDt-EfqkZ0qu1uYKnl-wOIsGeycsa9G8j45e4mkAnUpCCaGRB5obMcNs1KCZGZLvny7ZvanUM9Un0VmkN4bdcjc9RoeKe5YWbRGPnDgWq9dVQCK-3K5yktUoioUMIL7l-2fyEUc8lMjjTkemkSrVI8LgYy30-lxoYEF34Zjs3vlDljgkbg==" rel="nofollow" target="_blank">RTB</a> <a href="https://www.globenewswire.com/Tracker?data=Vj48FlFZ0rs_0PY1h0g5W_raV2vLzm3BfJuo8CdcVRV2vrpQSrsDz4QsOSfHfGzL-DlD7Gh6x6cNnlvxZ9CTjRdubgkiwqpteRyiLH0kRDbAF5Eaqc-O4E8ECyHQ9GqKbVb3wDUcCsCiVhBnmzgzW9mugb_GDkwEfS6rhm_psDK7aqVZh_QXqyRCOeUJiUxVOJ8PDSAHDp0ZqVg7u3CM65Poe8APws0q2haXA5aP2vlhEAxcE3A_5XP7w5_zdhWL6XbRpfBHaRV-acA8-K8m9etGbTVvZvk_9JT_rp_BmOlUHgsIkJukYIh2ZVABCz859FKALB8NK7F5mpapKyVpAhfuFehA-sm75XOZBX36PelqVw0o3aOvj4EPJKSFrx_uwguFgMGlmOoGcrmeg62FDw5IJdWmhmpFxzfgXzR5Jw6l_RY2hCasmIobNjbtKkTP0Qu7QzrP_oHKoxq_0lkhhsKwImQ0OlWjMKPw_nlDohn2naSSNoOqa9RvRO7E-N8EYxbz459S8ggZbmj6nytF5w==" rel="nofollow" target="_blank">(Ready</a> <a href="https://www.globenewswire.com/Tracker?data=BGZrXwkFO2U_GoPIJhJ0gFyFbJq0FhNAABz9Xw_BcZVI4DK0sgt1qKkuuOHZymRFmdDlR2VUSmgcjWZvursmaNM5eeMcZqiJlX7mypvQVnQB6zEH5emTVv3_LyzfR_caH_4AXRaSiJ3IRexlszqsVKrYX2Y3r7U1iWM48nvf8BhsElvZ22sFw1kvTE6BmJCCmmzW2zYOoREt8TFUuRmmzDPaodhgfKp_KT-2Q0Uie_vE-qCFsAclLYw7VipZl0P4evI15MenVnph2wTBNhaTLYYgzpc4nYdVjHSjjkiNTXloxxGRRuH8fLQjhvjVA14t34p6AW2Cd2bp81GyNWn_gTSKEe4L01Gd9LTshCK1e43YpTj1HxirnElr4bViXcaMTr20ueuN-zPY2_CHwNJum6831JlATIoK4jOqqp4m08btsEPPP5mVNoWQ7EEGah4-H8V3L5m8ry7IoHgvERXnDJbcRUJSVH-_hfhNh5w06guzEt-NrGeQR8Z6zZR83qRy" rel="nofollow" target="_blank">to</a> <a href="https://www.globenewswire.com/Tracker?data=pWXsDnAX9feCcgmi577fZMM4M5raFG6Xo7WE1cNrXgDGuXbViUZwSUH3PX5T8zBjNYTNUyJ-ootRr0FW-uyWwtocgmRth14ppeb2GCshr185Sz7o3RZP-cniER8vHhcbRXhpcn0Sv81qpxLLpiUR8wooLjmaS2xoZOLNlV71qQ5rUhQAfVvpYNARmax4EzUrSW_M4aomUQCDhHPIX72iz0SJH81kWjaa223ayAp99CjouXjegvc9WkVrLUCmgQSfNVMO5vaZ4rg9LL8DZOMwWXVy8Hto-ExDM87GI-VUUzwhU0T9bIFIi5ukiCtq2L9Hi1wIm0cZI97770my-3RjpD7-PhX6O3R2KOaCNpQdfVqoFO5IQCVk0Up6whGVCMxM1gypOLYr1LpQYQFS--96URe4AZ1heJ9hY469H7T9B93CDS1xiL8MGsQwsLvLe3Ln-RZBkU9KCjI_hY85VsrPEgqRux_YThV9GSRRYJHiVCH3dcZbaWyHvD198VXGMGULKiNiiCBKUwRgm275dRCSFw==" rel="nofollow" target="_blank">Build)</a> business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.</p>  <p align="justify">For additional details, please visit <a href="https://www.globenewswire.com/Tracker?data=Rh4R92RQbzlrDhvjhNziJY3AHFuKzNTZoxoZO4YscdPuMZlhEusVorDE1LfaKHAv-NpW-3-0w_HX86rgDYAbdSfQOA4LqMKnALE3VKBTtfk=" rel="nofollow" target="_blank">https://nexentistech.com/</a></p>  <p align="justify"><b>Forward-looking</b> <b>Statements:</b><br></br>This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses continued execution of its drug discovery strategy and tangible progress in translating the breadth of its platform into a focused, actionable pipeline decision. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause the Company’s and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 31, 2026 and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.</p>  <p align="justify">Investor Relations Contact:<br></br>Michal Efraty<br></br><a href="https://www.globenewswire.com/Tracker?data=5lJxpoYm2S7J0C1Ry-HtnfTx8q8a7_JyoyKOOIuRfbTtPT_SyFo18OFa0fVh7JsUwStHpt76csWbPCXVAwxJOjasLRX1hiDbinO_vSjZMVwN2u1gRM0Xek7X7AicNMfbB0OIOo2K85LEVYB5fxkwMSHEsFYkF_GWVCsI0xAvp0Pbi1nfjmTmQPt_IebWYxwtmpyCvzOKKYc0LTI4DALoShia1_pfBE-UPpn_Qi58wcZZ5cJg6hGfL-5Jh1_VBfKQ0vKXifOSbYAWnr4XRBcj6A==" rel="nofollow" target="_blank">michal@efraty.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc5OTIxNyM3NzQ2NDk2IzUwMDA1MzY2Ng=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NmEyMTk2YjQtNDhlNi00NDk0LTk5Y2ItOWZmYTkyYjc2NThkLTUwMDA1MzY2Ni0yMDI2LTA3LTI4LWVu/tiny/Nexentis-Technologies-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/0e0c11bd-6abb-4596-afc6-7033325e5030"><img src="https://ml.globenewswire.com/media/0e0c11bd-6abb-4596-afc6-7033325e5030/small/logo-jpg.jpg" border="0" width="150" height="44" alt="Primary Logo"></img></a></p>

Nexentis says its MitoCareX narrowed a broad SLC transport pool to a single, high-potential drug-discovery target using MITOLINE. The move advances its pipeline strategy and could yield near-term milestones or partnerships if the candidate progresses, while the company also highlights a solar RTB investment footing that could influence cash flow.

News insight

Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign

AI summary

Sentiment rationale

Key facts

Corporate Developments